Bioventus breidt uit naar Mexico met DUROLANE® tegen osteoarthritis in de knie
HOOFDDORP, Nederland–(BUSINESS WIRE)– Bioventus, leider in ortobiologische systemen, gaat de Mexicaanse markt voor patiëntzorg op. Deze bekendmaking laat zien dat het bedrijf blijft groeien op de internationale markt en weerspiegelt zijn missie samen te werken met zorgverleners, zodat mensen weer kunnen genieten van een actief leven. Het eerste product van Bioventus dat verkrijgbaar is in Mexico, is DUROLANE. Deze eenmalige injectie voor gewrichtsvloeistof steunt op een natuurlijke, veilige en bewezen technologie NASHA, die hyaluronzuur (HA) produceert. Hyaluronzuur is een molecuul dat in de natuur voorkomt. HA zorgt voor smering en schokdemping in een normaal gewricht. In Mexico is DUROLANE aangemerkt voor de behandeling van symptomen van milde tot matige osteoarthritis.
Bioventus Expands to Mexico with DUROLANE® for Knee Osteoarthritis Patients |
|||||
|
HOOFDDORP, The Netherlands–(BUSINESS WIRE)– Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to partner with the health care community to help people resume and enjoy active lives. The initial Bioventus product available in Mexico is DUROLANE a single-injection joint-fluid therapy based on a natural, safe and proven technology called NASHA ® which yields stabilized hyaluronic acid (HA). Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. In Mexico, DUROLANE is indicated for the symptomatic treatment of mild to moderate knee osteoarthritis (OA). “International expansion is a key part of our growth strategy at Bioventus and launching in Mexico gives us greater access in Latin America which has tremendous potential for us,” said Tony Bihl, CEO, Bioventus. “We now have orthobiologic solutions in more than 29 countries and expect to expand our global sales and marketing footprint even more in the months to come.” “ DUROLANE gives patients suffering from knee osteoarthritis another option for pain management,” said Isabelle Levy-Unger, Managing Director International, for Canada, Latin America and Asia Pacific, Bioventus. “It will be sold through Artimedica SA, a Mexican-based company that specializes in the sale and distribution of diagnostic, surgical and other healthcare products for hospitals and clinics across Mexico. We look forward to working with them to introduce this innovative single-injection solution to OA patients throughout the region.” “We are very excited to market DUROLANE in Mexico,” said Arnulfo Salazar Guerra, Legal Representative for Artimedica. “Its technology offers clear benefits for the estimated 6.7 million Mexican patients that suffer from knee osteoarthritis.” DUROLANE is available in Mexico now and is part of the Bioventus Active Healing Therapies portfolio which consists of products that allow patients to resume active lives using their bodies own processes to heal faster or reduce pain. More information is available at www.durolane.com. About Bioventus Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical, that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal. DUROLANE – Indications For the symptomatic treatment of mild to moderate knee osteoarthritis. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors. NASHA is a registered trademark of Galderma S.A. Bioventus, the Bioventus logo and DUROLANE are registered trademarks of Bioventus LLC. View source version on businesswire.com: http://www.businesswire.com/news/home/20161114005939/en/ Contacts Media Contacts: |
|||||